(WATCH) Rx Repeat: Lecanemab
Now an important update to our coverage of a new Alzheimer’s drug that drew so much controversy. Aducanumab was approved without one yes vote from the FDA advisory committee. In fact, several members quit over it. And critics say it offers no proof of real benefit but comes with significant health risks. Now, the FDA […]
Continue reading (WATCH) Rx Repeat: Lecanemab on sharylattkisson.com.
